Rucaparib or Physician's Choice in Metastatic Prostate Cancer

PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

Rucaparib extends PFS in advanced prostate cancer

ASCO GU 2023: Rucaparib Extends Survival for Metastatic, Castration-Resistant Prostate Cancer

The TRITON3 Study for mCRPC: Rucaparib or Physician's Choice?

Frontiers PARP inhibitors in metastatic prostate cancer

Current Oncology, Free Full-Text

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Cancers, Free Full-Text